Montag A & Associates Inc. Sells 523 Shares of Edwards Lifesciences Corp (NYSE:EW)

Montag A & Associates Inc. reduced its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 2.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,070 shares of the medical research company’s stock after selling 523 shares during the period. Montag A & Associates Inc.’s holdings in Edwards Lifesciences were worth $5,073,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. Quest Capital Management Inc. ADV purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $28,000. TRUE Private Wealth Advisors purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $26,000. Usca Ria LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $34,000. Evolution Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $29,000. Finally, M&R Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $29,000. 81.31% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently commented on EW. Stifel Nicolaus upped their price target on shares of Edwards Lifesciences from $215.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. Piper Jaffray Companies upped their price target on shares of Edwards Lifesciences from $240.00 to $255.00 and gave the company an “overweight” rating in a research note on Thursday, October 24th. BTIG Research restated a “hold” rating on shares of Edwards Lifesciences in a research note on Thursday, July 25th. ValuEngine cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, Cowen upped their price target on shares of Edwards Lifesciences from $250.00 to $265.00 and gave the company a “positive” rating in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $237.89.

In other news, VP Catherine M. Szyman sold 372 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $214.53, for a total transaction of $79,805.16. Following the sale, the vice president now owns 18,010 shares in the company, valued at approximately $3,863,685.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Michael A. Mussallem sold 22,850 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $216.70, for a total transaction of $4,951,595.00. Following the sale, the chief executive officer now owns 95,770 shares in the company, valued at approximately $20,753,359. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 140,734 shares of company stock worth $31,547,747. Corporate insiders own 1.63% of the company’s stock.

Shares of Edwards Lifesciences stock traded down $0.99 on Friday, hitting $234.16. 825,661 shares of the company traded hands, compared to its average volume of 1,239,245. The firm’s 50-day simple moving average is $226.42 and its 200 day simple moving average is $203.04. The company has a current ratio of 3.53, a quick ratio of 2.74 and a debt-to-equity ratio of 0.17. The company has a market cap of $48.47 billion, a P/E ratio of 49.82, a P/E/G ratio of 2.81 and a beta of 0.82. Edwards Lifesciences Corp has a 12-month low of $139.64 and a 12-month high of $241.82.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.19. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The business’s quarterly revenue was up 20.7% on a year-over-year basis. During the same quarter last year, the company posted $1.07 EPS. Analysts predict that Edwards Lifesciences Corp will post 5.6 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: Trading Stocks – What are percentage gainers?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply